Evaluation of Protective Effect of Gemigliptin and Rizatriptan in Streptozotocin induced Diabetic Neuropathy in Rats.

Abstract

ABSTRACT: A typical micro-vascular consequence of diabetes mellitus is diabetic neuropathy. The prevalence of diabetic neuropathy patients is rising in spite of strict glycemic control, blood pressure, and lipid lowering medication. New prevention and treatment methods are required because of the drawbacks and side effects of current medicines. Serotonin, a neurotransmitter implicated in the transmission of pain, is being investigated for its potential to process pain and to reduce inflammatory responses. Gemigliptin and rizatriptan are being studied for the treatment of hyperglycemic mortality. In this investigation, STZ (60 mg/kg) was injected intraperitoneally once to cause diabetic neuropathy. Tests were conducted on the neuroprotective potential of Gemigliptin (5 mg/kg p,o) alone and in combination with variable dosages of Rizatriptan (0.5, 1 mg/kg, i.p.) administered at intervals of 72 hours and one month. According to the study, a medicine combination of gemigliptin and rizatriptan successfully reduces the symptoms of diabetic neuropathy by lowering cholesterol, triglycerides, and serum glucose levels—all of which contribute to diabetes complications. Additionally, the combination reduces nerve damage-related hyperalgesia and significantly increases locomotor activity. Oxidative stress is decreased, which helps prevent additional difficulties, and the combination raises levels of antioxidants like SOD and CAT. Overall, Gemigliptin and Rizatriptan work well together to reduce diabetic neuropathic pain.